Skip to main content

Table 4 Important characteristics of studies for parallel validation

From: Structuring and validating a cost-effectiveness model of primary asthma prevention amongst children

Study

Model

Time Horizon

Perspective

Population

Intervention

Comparator

Effects

Nuijten [45]

Decision tree

Lifetime

UK National Health Service and society

Pre-term infants and children with BPD

Palivizumab

No prophylaxis

Number of RSV hospitalizations avoided

Omnes [46]

Decision tree

7 years (6 years-adults)

French Social Security

Children and adults

Specific immunotherapy (injectable and sublingual)

Current symptomatic treatment

Proportions of individuals with rhinitis or allergic asthma

Resch [47]

Decision tree

Lifetime

Austrian third party payer and society

Infants born premature or with BPD, and children with congenital heart disease

Palivizumab

No prophylaxis

Life years gained and QALY gained

ElHassan [48]

Markov (with and without increased asthma risk due to RSV infection)

1 year (no-risk); 8-10 years (with risk)

US society

Premature infants

Palivizumab

No prophylaxis

QALY gained

BrĂ¼ggenjĂ¼rgen [49]

Markov model

15 years

German third party payer and society

Children (6 to 12 years), adolescents (13 to 18 years), and adults (19 to 65 years)

Specific immunotherapy (subcutaneous) and symptom treatment

Symptom treatment

QALY gained

  1. QALY-quality-adjusted life year.
  2. BPD = bronchopulmonary dysplasia; RSV = respiratory syncytial virus; QALY = quality-adjusted life years